Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Dawn of a European Health Data Space – Opportunities

Posted on July 9th, 2020 by in Pharma R&D

At the beginning of 2020, the European Commission introduced a β€œEuropean strategy for data.” The document proposes to bolster and advance the data economy in Europe with a view towards capturing β€œthe benefits of better use of data, including greater productivity and competitive markets, but also improvements in health and well-being, environment, transparent governance and convenient public services.”

(more…)

5 Ways RWE is Fueling the Fight Against COVID-19

Posted on June 19th, 2020 by in COVID-19

As we discussed in an earlier blog post, real-world evidence can bring value to every stage of the drug life cycle, from early discovery to post-market. Now, as the worldwide research community continues to battle the COVID-19 pandemic, we are also discovering how real-world data and real-world evidence have something to offer in these efforts as well.

(more…)

The FAIR Toolkit Helps Researchers with Data Challenges

Posted on June 16th, 2020 by in Pharma R&D

Since the spread of COVID-19 was first reported, researchers of all types have mobilized to meet the challenges its causative agent, SARS-CoV-2, presents to the world. Data scientists in particular have been quick to apply their expertise to the problems of identifying, tracking and predicting outbreaks; diagnosing COVID-19; identifying infected individuals and detecting non-compliance with virus countermeasures; discovering new therapeutic interventions or repurposing existing ones; and searching for a safe, effective vaccine.

(more…)

Drug Repurposing for SARS-CoV-2 Using Network Polypharmacological Approach

Posted on June 9th, 2020 by in COVID-19

Drug development is a multidisciplinary field that requires a drug to successfully pass through different stages β€” from chemical design to biological experimentation on cells and animals, and finally three phases of human clinical trials β€” before being approved by the FDA for clinical administration. However, following such a path would not be feasible under circumstances where rapid discoveries are required, such as in the case of the current SARS-CoV-2 outbreak. Hence, repurpose of already approved FDA drugs could help in such circumstances, which can save effort, time and money.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. …
  6. 6